AI Summary & Key Takeaways
AI InsightMean high frequency power of HRV of the calcium antagonist group was significantly (p
📌 3 Key Takeaways
Abstract
Objective: The aim of this study was to investigate the effects of anti-anginal agents on plasma norepinephrine (NE) levels and the autonomic nerve functions evaluated by advanced noninvasive electrocardiographic (ECG) tests in post-myocardial infarction (PMI) patients. Methods: The subjects were 89 PMI patients who had suffered myocardial infarction (MI) at least 2 months before they participated in this study, and who had been taking anti-anginal agent mono-therapy (typical Japanese doses) for at least 6 months. Subjects were classified into the following 3 groups, based on type of anti-anginal agent: calcium antagonists (n=31, 60 ± 12 years), nitrates (n=29, 56 ± 11 years) and b-blockers (n=29, 63 ± 14 years). Left ventricular late potentials (LP), heart rate variability (HRV), T wave alternans (TWA), QT dispersion (QTd), and plasma NE levels of all subjects were assessed. There were no significant differences in age, gender, MI location or coronary risk factors between the 3 groups. Results: There were no significant differences in the number of subjects who satisfied criteria for LP, TWA, and QTd between the 3 groups. Mean high frequency power of HRV of the calcium antagonist group was significantly (p
Özet
Objective: The aim of this study was to investigate the effects of anti-anginal agents on plasma norepinephrine (NE) levels and the autonomic nerve functions evaluated by advanced noninvasive electrocardiographic (ECG) tests in post-myocardial infarction (PMI) patients. Methods: The subjects were 89 PMI patients who had suffered myocardial infarction (MI) at least 2 months before they participated in this study, and who had been taking anti-anginal agent mono-therapy (typical Japanese doses) for at least 6 months. Subjects were classified into the following 3 groups, based on type of anti-anginal agent: calcium antagonists (n=31, 60 ± 12 years), nitrates (n=29, 56 ± 11 years) and b-blockers (n=29, 63 ± 14 years). Left ventricular late potentials (LP), heart rate variability (HRV), T wave alternans (TWA), QT dispersion (QTd), and plasma NE levels of all subjects were assessed. There were no significant differences in age, gender, MI location or coronary risk factors between the 3 groups. Results: There were no significant differences in the number of subjects who satisfied criteria for LP, TWA, and QTd between the 3 groups. Mean high frequency power of HRV of the calcium antagonist group was significantly (p